Mode Diagnostics

Home Diagnostic Assaysmodehealth.com

Mode Diagnostics is a Glasgow-based diagnostics developer founded in 2007 that builds electrochemical biomarker assays for home diagnostic use; the firm is small (1-10 employees) and has shown no disclosed funding or operational activity since 2014.

Company typePrivate
Founded2007
HeadquartersGlasgow, United Kingdom
Headcount1–10
GTM typeB2C
OfferingHardware or Manufacturing

What Mode Diagnostics does

Mode Diagnostics is a Glasgow-based, privately held diagnostics company founded in 2007 that develops novel assays exploiting the electrochemical properties of biomarkers for home diagnostic use. Its stated technical approach centres on electrochemistry-based biomarker detection, a wet-lab chemistry platform intended to enable consumer or point-of-care diagnostic tests, though no specific products, regulatory milestones (e.g., CE marking, FDA clearance), or clinical validation data are disclosed in the available data.

The company is small, with 1-10 employees per firmographics, and has been funded primarily by Parkwalk Advisors across multiple disclosed rounds between 2010 and 2014 totalling roughly $2.66M, with no funding activity recorded since January 2014. The only disclosed leader is CEO Paul Heaney. No revenue, customer, pricing, or partnership information is available, and the company's intended website domain (ModeHealth.com) is currently listed for sale on the HugeDomains marketplace rather than being actively operated as a corporate site — a signal consistent with stalled or dormant operations. No AI/ML, regulatory actions, or product launches are disclosed.

Mode Diagnostics firmographics

Firmographics

Name: Mode Diagnostics
Website: https://modehealth.com
Company type: Private
Founded year: 2007
Headcount range: 1–10 employees
Short description: Mode Diagnostics is a Glasgow-based diagnostics developer founded in 2007 that builds electrochemical biomarker assays for home diagnostic use; the firm is small (1-10 employees) and has shown no disclosed funding or operational activity since 2014.
Ownership category
akta.pro rank

Mode Diagnostics industry classification

Industry

Product category: Home Diagnostic Assays
NAICS: In-Vitro Diagnostic Substance Manufacturing (325413)
SIC: In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro primary industry: Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)
akta.pro secondary industry: Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)

Keywords

Electrochemical biosensors
Biomarker assays
Home diagnostics
Point-of-care testing
Diagnostic kits

Where Mode Diagnostics is headquartered

Location

Headquarters

HQ city: Glasgow
HQ country: United Kingdom
HQ region: Europe

Markets served

Mode Diagnostics business model

Business model

GTM type: B2C
Offering type: Hardware or Manufacturing
Cost components: Personnel, Technology or R&D, Operations, Marketing or Sales

Pricing tiers

Model	Billing	Price
One time/ perpetual license	Pay-as-you-go	Domain name purchase (one-time)
Other	Monthly	Domain name purchase (payment plan)

Mode Diagnostics product offering

Product offering

Core offering

Mode Diagnostics develops novel diagnostic assays that exploit the electrochemical properties of biomarkers. The company's products are designed for home diagnostic purposes, providing consumers with assay-based testing tools that rely on electrochemistry-driven detection of biomarkers.

Differentiator

Problem solved

Functional benefit

Products and services

Electrochemical biomarker diagnostic assays

Companies that use Mode Diagnostics

Customer profile

Ideal customer profiles1 record

Mode Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Mode Diagnostics partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights1 record

Mode Diagnostics competitors and assessment

Company assessment

Direct peers

Nova Biomedical: Manufacturer of blood chemistry analyzers and electrochemical biosensors for clinical and point-of-care use. Comparable because both companies leverage electrochemical transducer approaches to measure biomarker concentrations in blood and related samples.
EKF Diagnostics Holdings: UK-based diagnostics company developing point-of-care and clinical chemistry analyzers, including electrochemical hemoglobin and diabetes assays. Comparable to Mode Diagnostics as a UK-headquartered diagnostics developer targeting near-patient/home-relevant electrochemical biomarker measurements.
Atomo Diagnostics: Developer of integrated rapid diagnostic test platforms for diseases such as HIV and infectious disease. Comparable as a small-cap diagnostics company building user-friendly, near-patient assay platforms with home or self-test appeal.
ACON Laboratories: Manufacturer of rapid diagnostic test kits and consumer/self-test products, including glucose meters and infectious disease assays. Comparable for its portfolio of home-use diagnostic kits targeting biomarkers and analytes via electrochemical and lateral-flow methods.

Emerging players

Quotient Limited: Developer of diagnostic blood testing platforms intended for near-patient and decentralized settings. Comparable because it pursues biomarker testing in non-centralized environments, overlapping with Mode's home-diagnostic ambition.
Profusa: Developer of injectable biosensors and readers for continuous monitoring of body chemistries. Comparable as a small company building novel biomarker sensing platforms aimed at decentralized and home-oriented monitoring.
Senseonics: Developer of long-term implantable continuous glucose sensors using electrochemical detection. Comparable as a peer using electrochemical sensing for biomarker monitoring outside the central lab.
Biolinq: Developer of intradermal biosensor patches for continuous biomarker monitoring. Comparable as an emerging electrochemical biosensor company pursuing home- and wearable-style diagnostic use cases.

Broad incumbents

Dexcom: Global leader in continuous glucose monitoring using subcutaneous electrochemical sensors. Comparable as a commercial-stage example proving that electrochemical biosensors can support large-scale, home-based diagnostic and monitoring workflows.
Abbott Diagnostics: Major diagnostics incumbent spanning immunoassay, blood screening, and consumer self-tests (e.g., BinaxNOW). Comparable as the dominant incumbent that any home-biomarker assay entrant such as Mode Diagnostics would have to differentiate against.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Mode Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mode Diagnostics leadership team

Management profile

Number of profiles

Profiles1 record

Mode Diagnostics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mode Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mode Diagnostics

What does Mode Diagnostics do?

When was Mode Diagnostics founded?

Mode Diagnostics was founded in 2007. It employs 1 to 10 people.

Where is Mode Diagnostics based?

Mode Diagnostics is headquartered in Glasgow, United Kingdom, in the Europe region.

Who are Mode Diagnostics's main competitors?

Direct peers on record are Nova Biomedical, EKF Diagnostics Holdings, Atomo Diagnostics and ACON Laboratories. Emerging players are Quotient Limited, Profusa, Senseonics and Biolinq. Broad incumbents are Dexcom and Abbott Diagnostics.

Does Mode Diagnostics have an API?

No public API is recorded for Mode Diagnostics.

What industry is Mode Diagnostics in?

Mode Diagnostics's product category is Home Diagnostic Assays. Its primary akta.pro industry code is HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.